Universitätsklinikum Münster
Welcome,         Profile    Billing    Logout  
 12 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stelljes, Matthias
IDUNN, NCT04629833 / 2019-001462-15: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting
3
210
Europe
MC0518, BAT
medac GmbH
Steroid-refractory Acute Graft-versus-host Disease
08/27
08/30
GRAPPA, NCT05153226: GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG

Active, not recruiting
3
640
Europe
Cyclophosphamide, all brands, ATG, ATG Grafalon
DKMS gemeinnützige GmbH
Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS, MDS/MPN, CMML
06/25
12/26
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33
HAMLET, NCT03275636 / 2015-005399-12: Haploidentical Donor vs mMUD in Hematological Malignancies

Completed
2/3
98
Europe
Peripheral blood stem cells, PBSC
DKMS gemeinnützige GmbH
AML, ALL, MDS
04/24
04/24
NCT04232241: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Recruiting
2
440
Europe, RoW
Allogeneic Stem Cell Transplantation
Universitätsklinikum Hamburg-Eppendorf, DKMS Stiftung Leben Spenden, Clinical Trial Center North (CTC North GmbH & Co. KG)
Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes
11/22
11/24
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
12/24
07/29
INITIAL-1, NCT03460522 / 2016-004836-39: Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

Recruiting
2
65
Europe
Inotuzumab ozogamicin
Nicola Goekbuget, Pfizer Pharma GmbH
Precursor Cell Lymphoblastic Leukemia
06/25
12/25
NCT03853616 / 2017-002848-32: MB-CART19.1 R/r CD19+ B-cell Malignancies (BCM)

Recruiting
1/2
48
Europe
MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells
Miltenyi Biomedicine GmbH
Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent, Chronic Lymphocytic Leukemia Refractory
12/24
12/24
BlastCrisis, NCT03869502: European CML Blast Crisis Register

Recruiting
N/A
250
Europe, RoW
University of Jena
Chronic Myeloid Leukemia in Myeloid Blast Crisis
06/24
06/24
Kerkhoff, Andrea
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Completed
3
430
Europe
Ramucirumab, TAS 102
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH
Colorectal Cancer
07/24
07/24
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
Alternative-C, NCT05387616: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

Active, not recruiting
2
98
Europe
Copanlisib, ALIQOPA™, Obinutuzumab, GAZYVARO®
Ludwig-Maximilians - University of Munich, Roche Pharma AG, Bayer
Follicular Lymphoma
09/23
05/26
R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Recruiting
2
125
Europe
Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
04/25
09/28
ACCELERATE, NCT02817997: International Registry for Patients With Castleman Disease

Recruiting
N/A
1000
US
University of Pennsylvania, EUSA Pharma, Inc., Castleman Disease Collaborative Network, Food and Drug Administration (FDA)
Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node, Lymph Node Hyperplasia, Giant
09/26
09/26
Schmidt, Eva
No trials found
Eßeling, Eva
No trials found
Becker, Heidemarie
No trials found

Download Options